| Autor: |
Rishi Jayant Khusial, Jacob K Sont, Omar S Usmani, Matteo Bonini, Kian Fan Chung, Stephen James Fowler, Persijn J Honkoop |
| Jazyk: |
angličtina |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
JMIR Cardio, Vol 8, p e56848 (2024) |
| Druh dokumentu: |
article |
| ISSN: |
2561-1011 |
| DOI: |
10.2196/56848 |
| Popis: |
BackgroundBeta-2 agonists play an important role in the management of asthma. Inhaled long-acting beta-2 agonists (LABAs) and short-acting beta-2 agonists (SABAs) cause bronchodilation by stimulating adrenoceptors. These receptors are also present in cardiac cells and, as a side effect, could also be stimulated by inhaled beta-2 agonists. ObjectiveThis study aims to assess the effect of beta-2 agonists on heart rate (HR). MethodsThe data were retrieved from an observational study, the myAirCoach Quantification Campaign. Beta-2 agonist use was registered by self-reported monthly questionnaires and by smart inhalers. HR was monitored continuously with the Fitbit Charge HR tracker (Fitbit Inc). Patients (aged 18 years and older) were recruited if they had uncontrolled asthma and used inhalation medication. Our primary outcome was the difference in HR between LABA and non-LABA users. Secondary outcomes were the difference in HR on days SABAs were used compared to days SABAs were not used and an assessment of the timing of inhaler use during the day. ResultsPatients using LABA did not have a clinically relevant higher HR (average 0.8 beats per minute difference) during the day. Around the moment of SABA inhalation itself, the HR does increase steeply, and it takes 138 minutes before it returns to the normal range. ConclusionsThis study indicates that LABAs do not have a clinically relevant effect on HR. SABAs are instead associated with a short-term HR increase. Trial RegistrationClinicalTrials.gov NCT02774772; https://clinicaltrials.gov/study/NCT02774772 |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
